XML 29 R7.htm IDEA: XBRL DOCUMENT v3.24.4
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss $ (7,546,328) $ (4,952,223) $ (6,592,723) $ (4,996,069)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation 3,667 4,828 6,811 5,972
Change in fair value of derivative liability (340,405) (2,118,175) (2,216,488) 189,000
Change in fair value of warrant liabilities     398,675
Amortization of debt discount and finance fees 1,079,444 1,654,724 2,123,049 377,384
Gain on marketable securities (100,118) (1,744) (4,970)
Change in fair value of marketable securities 71,568 (21,134) (71,568)
Accrued interest settled with common stock 54,670 294,927 294,927
Loss on settlement of notes payable and convertible notes payable, as restated 833,501 477,221 477,221 1,795,652
Fair value of freestanding instruments in excess of proceeds, as restated     189,912
Gain on settlement on accounts payable     (328,687)
Gain on forgiveness of Paycheck Protection Program     (73,007)
Stock-based compensation, as restated 227,886 95,438 181,960 237,547
Changes in operating assets and liabilities:        
Accrued interest income 14,897 (12,435) (14,901)
Prepaid expenses 11,433 (8,956) 46,675 (156,282)
Accounts payable and accrued expenses 1,065,584 63,255 166,115 (382,881)
Accounts payable and accrued expenses - related parties (446) (12,500) (12,054) 12,500
Accrued interest payable, as restated (15,056) 106,578 110,453 18,378
Accrued interest payable - related parties 2,137 (98,135) (98,135) 51,188
Other assets     6,480
Change in operating lease asset and liabilities 498 9,358 16,001 (5,693)
Net cash used in operating activities (4,637,068) (4,518,973) (5,581,147) (2,666,411)
CASH FLOWS FROM INVESTING ACTIVITIES:        
Investment in marketable securities (43,587) (2,977,714) (2,998,572)
Proceeds from disposition of marketable securities 2,959,352 80,000 187,895
Purchase of equipment (19,046) (19,046)
Net cash provided by (used in) investing activities 2,915,765 (2,916,760) (2,829,723)
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from issuance of common shares and exercise of warrants, as restated     9,995,513
Proceeds from note payable-related party 250,000 50,000
Repayment of note payable-related party (685,473) (685,473) (50,000)
Proceeds from convertible notes payable 3,935,000 3,935,000 550,715
Proceeds from notes payable and warrants, as restated     50,000
Payment for finance costs related to convertible note payable (345,000) (345,000) (17,363)
Payment for finance costs (101,651)    
Payment of convertible note payable (846,806) (334,444)
Net cash provided by (used in) financing activities (698,457) 2,904,527 2,570,083 10,578,865
Net change in cash and cash equivalents (2,419,760) (4,531,206) (5,840,787) 7,912,454
Cash and cash equivalents, beginning of period 2,576,416 8,417,203 8,417,203 504,749
Cash and cash equivalents, end of period 156,656 3,885,997 2,576,416 8,417,203
Cash paid for:        
Interest 79,682 102,373 164,807 39,201
Income taxes
Supplemental non-cash financing activities:        
Common stock issued for settlement of debt 1,947,294 2,697,849    
Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively, as restated 90,816 90,816 14,662
Initial recognition of right of use asset and liability $ 365,556 365,556
Common stock issued for conversion of accrued interest, as restated     16,340
Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated     2,697,849 1,199,916
Common stock issued for exercise of warrants with settlement of notes payable, as restated     $ 2,153,124
Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated     402,064
Reclassification of fair value of warrant liabilities to equity, as restated     $ 881,553